bemcentinib: Clinical Trials

7 trials of bemcentinib, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

4 completed, 3 terminated. 7 Phase 1, 5 Phase 2.

By phase and status

PhaseTrialsStatus
Phase 17Completed 4, Terminated 3
Phase 25Terminated 3, Completed 2

Follow bemcentinib: new trials by email Literature Review of bemcentinib trials Research Report on bemcentinib

Trials (filtered) newest first · largest first

All 7 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Study of Bemcentinib Plus Pacritinib In Patients With Advanced Lung Adenocarcinoma
bemcentinib, pacritinib - Advanced Lung Adenocarcinoma
Phase 1 / Phase 2TerminatedThe University of Texas Health Science Center at San Antonio42024-12-272026-05-26
A Clinical Study of Bemcentinib With Standard of Care Chemoimmunotherapy in Untreated Advanced/Metastatic Non-small Cell Lung Cancer Patients With a Mutation in the STK11 Gene
Bemcentinib, Pembrolizumab, Pemetrexed - Carcinoma, Non-Small-Cell Lung
Phase 1 / Phase 2TerminatedBerGenBio ASA262023-03-032025-10-29
A Study to Investigate 14C-bemcentinib in Healthy Male Subjects
Bemcentinib - Non-Small Cell Lung Cancer, Metastatic Melanoma
Phase 1CompletedBerGenBio ASA62022-08-022025-01-29
Clinical Trial of Chemotherapy and Bemcentinib for Metastatic Pancreatic Cancer
Bemcentinib, Nab-paclitaxel, Gemcitabine - Cancer of Pancreas
Phase 1 / Phase 2TerminatedUniversity of Texas Southwestern Medical Center92019-01-032023-11-09
Trial of Dose Escalated BGB324 in Previously Treated Non-small Cell Lung Cancer.
BGB324, Docetaxel - Non-Small Cell Lung Carcinoma
Phase 1CompletedUniversity of Texas Southwestern Medical Center232016-11-012024-02-21
A Study of BGB324 (Bemcentinib) in Combination With Erlotinib in Patients With Non-Small Cell Lung Cancer
Erlotinib, Bemcentinib - Non-Small Cell Lung Cancer
Phase 1 / Phase 2CompletedBerGenBio ASA402015-04-192025-02-26
A Phase Ib/II Multicenter Open-label Study of Bemcentinib (BGB324) in Patients With AML or MDS
Bemcentinib, Cytarabine, Decitabine - Acute Myeloid Leukemia, Myelodysplastic Syndromes
Phase 1 / Phase 2CompletedBerGenBio ASA1222014-10-222024-12-19

Conditions studied

Carcinoma, Non-Small-Cell Lung (4)  ·  Leukemia, Myeloid, Acute (2)  ·  Myelodysplastic Syndromes (2)  ·  Pancreatic Neoplasms (2)  ·  COVID-19 (1)  ·  Glioblastoma (1)  ·  Melanoma (1)  ·  Mesothelioma, Malignant (1)

Sponsors

BerGenBio ASA (4)  ·  University of Texas Southwestern Medical Center (2)  ·  The University of Texas Health Science Center at San Antonio (1)

Countries

United States (6)  ·  Italy (2)  ·  France (1)  ·  Germany (1)  ·  Greece (1)  ·  Hungary (1)  ·  Norway (1)  ·  Poland (1)  ·  Spain (1)  ·  United Kingdom (1)

Top investigators

David E Gerber, MD (1)  ·  Dr. Lauren Byers, MD (1)  ·  Sonja Loges, MD (1)  ·  Syed Kazmi, MD (1)

Results publications

PMID 40122885

NIH funding

R01CA269766 (1)